60 related articles for article (PubMed ID: 22261410)
1. HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.
Liao Q; Strong AJ; Liu Y; Liu Y; Meng P; Fu Y; Touzjian N; Shao Y; Zhao Z; Lu Y
Vaccine; 2012 Feb; 30(9):1601-8. PubMed ID: 22261410
[TBL] [Abstract][Full Text] [Related]
2. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
3. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.
Stahl-Hennig C; Suh YS; Park KS; Sauermann U; Kim KS; Ahn S; Franz M; Schulte R; Stolte-Leeb N; Hunsmann G; Sung YC
J Med Primatol; 2007 Aug; 36(4-5):195-205. PubMed ID: 17669208
[TBL] [Abstract][Full Text] [Related]
5. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
6. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
[TBL] [Abstract][Full Text] [Related]
7. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a new HIV-1 DNA construct in a BALB/c mouse model.
Mahdavi M; Ebtekar M; Mahboudi F; Khorram Khorshid H; Rahbarizadeh F; Azadmanesh K; Darabi H; Pourasgari F; Hassan ZM
Iran J Immunol; 2009 Dec; 6(4):163-73. PubMed ID: 20054104
[TBL] [Abstract][Full Text] [Related]
9. Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct.
Cardinaud S; Bouziat R; Rohrlich PS; Tourdot S; Weiss L; Langlade-Demoyen P; Burgevin A; Fiorentino S; van Endert P; Lemonnier FA
AIDS; 2009 Sep; 23(15):1945-54. PubMed ID: 19644347
[TBL] [Abstract][Full Text] [Related]
10. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR
Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317
[TBL] [Abstract][Full Text] [Related]
11. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
13. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses.
Mahdavi M; Ebtekar M; Khorram Khorshid HR; Azadmanesh K; Hartoonian C; Hassan ZM
Immunol Lett; 2011 Oct; 140(1-2):14-20. PubMed ID: 21679728
[TBL] [Abstract][Full Text] [Related]
14. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
17. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs.
Ellenberger D; Wyatt L; Li B; Buge S; Lanier N; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Vogt J; Smith J; Otten R; Montefiori D; Kraiselburd E; Moss B; Robinson H; McNicholl J; Butera S
Virology; 2005 Sep; 340(1):21-32. PubMed ID: 16023165
[TBL] [Abstract][Full Text] [Related]
18. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
[TBL] [Abstract][Full Text] [Related]
19. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
20. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
